Merck & Co.'s Solid Growth Turbo-Charged By Lagevrio For COVID-19
Executive Summary
Even without Lagevrio, Merck's base business grew by double digits; the company raised its revenue guidance for the year.
You may also be interested in...
Bristol’s Opdivo Stumbles On Its Way To First-Line Bladder Cancer Indication
The CheckMate-901 trial failed on one of its primary endpoints, but the company will continue the trial to explore additional primary endpoints.
ICER Gives Cold Shoulder To Merck/Ridgeback’s COVID-19 Pill
Group’s final report said evidence was inadequate to demonstrate a net health benefit versus symptomatic care for Lagevrio, a drug that has already taken a back seat to Pfizer’s Paxlovid.
BMS’s Revlimid Loss Of Exclusivity Is Not As Bad As Expected, But Not For Long
The company credited generics’ late market entry, but that benefit is not expected to last; the firm lowered guidance for annual sales of the oncologic.